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Background: The BTI stent is a unique fully bioabsorbable sirolimus-eluting stent synthesized entirely from salicylic acid polymer derivates. 
We sought to assess this completely biodegradable stent (8.3μg sirolimus/mm) with optical coherence tomography (OCT) up to 18 month post 
implantation in pig coronary artery model.
Methods: Fully bioabsorbable balloon-expandable stents (n=93) were implanted in pig coronaries using QCA to optimize stent apposition. Animals 
underwent restudy at 1 month (1M), 3 month (3M), 6 month (6M), 9 month (9M), 12 month (12M), 15 month (15M), and 18 month (18M). Stent 
area, lumen area, strut thickness and strut area were measured by OCT.
Results: Though stent strut area could not be measured due to nearly disappearance of stent struts after 12M, stent struts maintained sufficient 
area up to 12M (1M: 6.50 mm2 vs. 3M: 6.40 mm2, P=0.76, 3M vs. 6M: 6.55mm2, P=0.62, 6M vs. 9M: 6.76 mm2, P=0.52, 9M vs. 12M: 5.96 
mm2, P=0.05). In contrast lumen area was significantly increased from 3M to 6M (3M: 2.58 mm2 vs. 6M: 3.29 mm2, P<0.05) and then maintained 
sufficient area over time (6M vs. 9M: 3.74 mm2, P=0.13, 9M vs. 12M: 3.39 mm2, P=0.30, 12M vs. 15M: 3.97 mm2, P=0.08, 15M vs. 18M: 
4.25 mm2, P=0.44). Average strut thickness and area measured by OCT at 1M was similar to post implantation (implant: 0.25mm, 0.14mm2, 
1M: 0.26mm, 0.121mm2), then gradually decreased over time (3M: 0.23mm and 0.093mm2; 6M: 0.19mm and 0.070mm2, 9M: 0.18mm and 
0.066mm2, 12M: 0.16mm and 0.055mm2, 15M: 0.15mm and 0.053mm2, 18M: 0.13mm and 0.021mm2, respectively, P<0.05). Histologic analysis 
confirmed these in-vivo findings and revealed a favorable healing process of absorbable stent incorporation into the arterial wall, without excessive 
thrombotic or inflammatory reactions.
Conclusions: A novel fully bioabsorbable salicylate-based stent maintains lumen area and didn’t show acute and/or chronic recoil during long 
term follow up. Furthermore, OCT demonstrated gradual degradation of this stent which was remarkably decreased from 1M to 18M.
